Prothena Co. PLC (PRTA) Given Average Rating of “Buy” by Brokerages

Prothena Co. PLC (NASDAQ:PRTA) has been assigned a consensus recommendation of “Buy” from the fifteen ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $76.11.

Several research firms have recently commented on PRTA. Oppenheimer reaffirmed a “buy” rating and issued a $70.00 target price on shares of Prothena in a research report on Thursday, November 9th. Zacks Investment Research downgraded Prothena from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Deutsche Bank set a $73.00 target price on Prothena and gave the company a “buy” rating in a research report on Monday, October 23rd. Wedbush downgraded Prothena from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $75.00 to $55.00 in a research report on Monday, November 20th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $79.00 target price on shares of Prothena in a research report on Thursday, September 28th.

Hedge funds have recently modified their holdings of the stock. ProShare Advisors LLC lifted its stake in Prothena by 1.0% during the second quarter. ProShare Advisors LLC now owns 22,910 shares of the biotechnology company’s stock worth $1,240,000 after purchasing an additional 216 shares during the last quarter. Ameritas Investment Partners Inc. lifted its stake in Prothena by 8.3% during the second quarter. Ameritas Investment Partners Inc. now owns 3,249 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 250 shares during the last quarter. Principal Financial Group Inc. lifted its stake in Prothena by 4.3% during the second quarter. Principal Financial Group Inc. now owns 6,808 shares of the biotechnology company’s stock worth $368,000 after purchasing an additional 280 shares during the last quarter. Cornerstone Capital Management Holdings LLC. lifted its stake in Prothena by 2.3% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 18,018 shares of the biotechnology company’s stock worth $974,000 after purchasing an additional 402 shares during the last quarter. Finally, Nationwide Fund Advisors lifted its stake in Prothena by 0.9% during the second quarter. Nationwide Fund Advisors now owns 46,504 shares of the biotechnology company’s stock worth $2,517,000 after purchasing an additional 407 shares during the last quarter.

Prothena (PRTA) traded down $0.17 during trading on Friday, hitting $39.52. The stock had a trading volume of 334,434 shares, compared to its average volume of 371,633. Prothena has a 52 week low of $34.85 and a 52 week high of $70.00. The firm has a market capitalization of $1,510.00, a P/E ratio of -9.32 and a beta of 2.43.

Prothena (NASDAQ:PRTA) last posted its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.37) EPS for the quarter, beating the consensus estimate of ($1.41) by $0.04. Prothena had a negative return on equity of 34.40% and a negative net margin of 562.19%. The company had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.28 million. During the same quarter in the prior year, the business earned ($1.26) earnings per share. The firm’s revenue for the quarter was down 33.6% on a year-over-year basis. equities analysts anticipate that Prothena will post -4.27 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2018/01/20/prothena-co-plc-prta-given-average-rating-of-buy-by-brokerages.html.

Prothena Company Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Analyst Recommendations for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply